CA Stock MarketDetailed Quotes
MDMA Pharmala Biotech Holdings Inc
- 0.335
- +0.025+8.06%
15min DelayMarket Closed Nov 19 15:59 ET
32.14MMarket Cap-41875P/E (TTM)
0.340High0.305Low494.78KVolume0.305Open0.310Pre Close160.34KTurnover0.35052wk High0.52%Turnover Ratio95.94MShares0.06552wk Low-0.008EPS TTM32.14MFloat Cap0.540Historical HighLossP/E (Static)95.94MShs Float0.005Historical Low-0.01EPS LYR11.29%Amplitude--Dividend TTM23.93P/B1Lot Size--Div YieldTTM
Pharmala Biotech Holdings Inc Key Stats
Quarterly+Annual
YOY
| (Q2)Feb 29, 2024 | (Q1)Nov 30, 2023 | (FY)Aug 31, 2023 | (Q4)Aug 31, 2023 | (Q3)May 31, 2023 | (Q2)Feb 28, 2023 | (Q1)Nov 30, 2022 | (FY)Aug 31, 2022 | (Q4)Aug 31, 2022 | (Q3)May 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -1,655.37%-106.61K | 1,097.14%14.32K | 45.69%-339.66K | -140.19%-31.52K | 23.50%-313.56K | 131.09%6.85K | 99.47%-1.44K | -260.29%-625.37K | 78.41K | -409.88K |
| Net income from continuing operations | -207.97%-222.57K | 112.64%36.48K | 20.88%-779.81K | 58.06%-80.3K | -64.37%-338.74K | 74.67%-72.27K | 4.70%-288.5K | 60.72%-985.58K | ---191.45K | ---206.08K |
| Depreciation and amortization | 19.72%15.78K | 19.84%15.79K | 334.82%52.77K | 20.37%13.23K | 2,861.35%13.18K | 2,861.35%13.18K | 5,108.70%13.18K | 3,904.95%12.14K | --10.99K | --445 |
| Asset impairment expenditure | ---- | ---- | --16.86K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Remuneration paid in stock | 228.16%56.59K | -53.92%18.78K | -71.37%67.73K | -95.80%5.28K | -69.24%4.45K | -47.80%17.25K | -35.81%40.75K | 65.85%236.53K | --125.54K | --14.47K |
| Other non cashItems | ---90.42K | --114.59K | ---74.06K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | 175.18%134.01K | -173.49%-171.32K | 237.85%376.86K | -34.39%87.47K | 103.45%7.56K | -78.81%48.7K | 809.29%233.14K | 2.33%111.55K | --133.32K | ---218.71K |
| -Change in receivables | -147.83%-19.2K | 90.60%-7.06K | -1,382.06%-115.74K | -350.29%-138.38K | 289.10%57.6K | 199.24%40.15K | -264.51%-75.12K | 130.63%9.03K | --55.29K | --14.8K |
| -Change in inventory | --0 | --112.03K | 94.97%-5.85K | 348.76%95.94K | ---101.79K | --0 | --0 | ---116.34K | ---38.57K | ---- |
| -Change in prepaid assets | -237.96%-320.65K | 14.00%44.16K | 2,086.02%284.42K | -170.29%-31.02K | 96.27%44.28K | 399.57%232.43K | 1,229.30%38.74K | ---14.32K | --44.14K | --22.56K |
| -Change in payables and accrued expense | 209.14%144.3K | 977.48%9.12K | -8.21%214.04K | 122.10%160.94K | 104.19%7.46K | -86.58%46.68K | 88.24%-1.04K | 68.39%233.18K | --72.46K | ---178.3K |
| -Change in other working capital | ---- | -221.81%-329.57K | ---- | ---- | ---- | ---- | --270.55K | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -1,655.37%-106.61K | 1,097.14%14.32K | 45.69%-339.66K | -140.19%-31.52K | 23.50%-313.56K | 131.09%6.85K | 99.47%-1.44K | -260.29%-625.37K | --78.41K | ---409.88K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -69.78%-75.9K | 53.00%-56.51K | 49.07%-506.74K | 36.92%-269.44K | 69.57%-72.37K | 83.83%-44.7K | -125.00%-120.23K | -258.11%-994.87K | -427.14K | -237.84K |
| Net PPE purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | -12.07%-2.99K | --0 | --0 |
| Net intangibles purchas and sale | -69.78%-75.9K | 53.00%-56.51K | 48.91%-506.74K | 36.92%-269.44K | 69.57%-72.37K | 83.83%-44.7K | -138.33%-120.23K | -282.20%-991.88K | ---427.14K | ---237.84K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -69.78%-75.9K | 53.00%-56.51K | 49.07%-506.74K | 36.92%-269.44K | 69.57%-72.37K | 83.83%-44.7K | -125.00%-120.23K | -258.11%-994.87K | ---427.14K | ---237.84K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 70K | 189.3K | 0 | 150.2K | 39.1K | 0 | 0 | 0 | 0 |
| Proceeds from stock option exercised by employees | --0 | --70K | --189.3K | --0 | --189.3K | --0 | --0 | --0 | --0 | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | --70K | --189.3K | --0 | --150.2K | --39.1K | --0 | --0 | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -69.49%222.85K | -77.11%195.04K | -65.53%852.14K | -58.70%495.99K | -60.42%731.72K | -65.98%730.47K | -65.53%852.14K | --2.47M | --1.2M | --1.85M |
| Current changes in cash | -14,665.04%-182.5K | 122.85%27.81K | 59.44%-657.1K | 13.70%-300.95K | 63.61%-235.73K | 100.42%1.25K | 62.60%-121.67K | -165.53%-1.62M | ---348.74K | ---647.72K |
| End cash Position | -94.49%40.35K | -69.49%222.85K | -77.11%195.04K | -77.11%195.04K | -58.70%495.99K | -60.42%731.72K | -65.98%730.47K | -65.53%852.14K | --852.14K | --1.2M |
| Free cash from | -382.20%-182.5K | 65.32%-42.2K | 47.76%-846.39K | 13.70%-300.95K | 40.42%-385.92K | 87.32%-37.85K | 62.60%-121.67K | -271.82%-1.62M | ---348.74K | ---647.72K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Latest Price
% Chg
No Data